Summary
Medtronic plc (MDT) reported financial results for the six-month period ending October 27, 2017. The company experienced significant top-line decline in net sales for the quarter, primarily due to the divestiture of its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. However, net income attributable to Medtronic saw a substantial increase of 81% for the three-month period and 48% for the six-month period compared to the prior year, driven by a significant gain on the sale of these divested businesses and favorable tax adjustments. The company's core segments, particularly Cardiac and Vascular Group, demonstrated growth, while Minimally Invasive Therapies Group was heavily impacted by the divestiture and Hurricane Maria. Free cash flow generation remained strong, though lower than the prior year, reflecting strategic capital allocation and operational efficiencies. Despite the revenue headwinds from the divestiture and a hurricane impact, Medtronic managed its expenses effectively, leading to improved profitability metrics on a GAAP basis. The company's strategic focus on therapy innovation, globalization, and economic value continues to guide its operations. Investors should note the significant one-time gains from divestitures and tax benefits that boosted net income, and consider these in conjunction with the underlying operational performance of the core business segments.
Financial Highlights
54 data points| Revenue | $7.05B |
| Cost of Revenue | $2.12B |
| Gross Profit | $4.93B |
| SG&A Expenses | $2.54B |
| Operating Income | $1.89B |
| Interest Expense | $273.00M |
| Net Income | $2.02B |
| EPS (Basic) | $1.49 |
| EPS (Diluted) | $1.48 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.37B |
Key Highlights
- 1Net sales decreased by 4% for the three months and remained flat for the six months ended October 27, 2017, largely due to the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses and the impact of Hurricane Maria.
- 2Net income attributable to Medtronic surged by 81% for the three months and 48% for the six months ended October 27, 2017, primarily driven by a $697 million gain on the sale of divested businesses and significant tax benefits.
- 3The Cardiac and Vascular Group showed strong growth, with net sales increasing by 7% for the three months and 6% for the six months, driven by key product performance.
- 4The Minimally Invasive Therapies Group experienced a significant net sales decline of 21% for the three months and 9% for the six months, heavily impacted by the aforementioned divestiture.
- 5Operating cash flow decreased by $1.4 billion for the six months ended October 27, 2017, mainly due to higher tax payments and retirement benefit funding, impacting free cash flow.
- 6The company repurchased $1.9 billion of ordinary shares during the six-month period, demonstrating a commitment to returning capital to shareholders.
- 7Medtronic successfully navigated a temporary IT system disruption in June 2017, concluding its impact was not material to revenue or earnings per share for the six-month period.